Fielder Capital Group LLC Reduces Stock Position in Medpace Holdings, Inc. $MEDP

Fielder Capital Group LLC lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 641 shares of the company’s stock after selling 56 shares during the period. Fielder Capital Group LLC’s holdings in Medpace were worth $201,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MEDP. Mawer Investment Management Ltd. acquired a new stake in Medpace in the first quarter valued at approximately $212,131,000. Vulcan Value Partners LLC grew its position in shares of Medpace by 221.6% in the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock valued at $99,159,000 after purchasing an additional 224,578 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Medpace by 675.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock worth $37,009,000 after purchasing an additional 105,807 shares in the last quarter. Invesco Ltd. lifted its stake in Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock valued at $361,596,000 after buying an additional 102,015 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Medpace by 36.0% in the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock worth $102,830,000 after buying an additional 89,347 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total value of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares in the company, valued at $27,600,000. This trade represents a 14.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel owned 10,343 shares of the company’s stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 107,465 shares of company stock valued at $49,720,216 in the last quarter. Corporate insiders own 20.30% of the company’s stock.

Medpace Price Performance

Shares of MEDP opened at $605.20 on Friday. The firm has a 50-day simple moving average of $503.13 and a two-hundred day simple moving average of $392.06. The stock has a market cap of $17.00 billion, a PE ratio of 42.32, a P/E/G ratio of 3.58 and a beta of 1.40. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $625.00.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. During the same period last year, the business posted $3.01 earnings per share. The company’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Cowen restated a “sell” rating on shares of Medpace in a research report on Friday. Barclays upped their price objective on shares of Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a research note on Friday. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, September 22nd. Weiss Ratings reissued a “buy (b-)” rating on shares of Medpace in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $464.00.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.